Literature DB >> 19491652

HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.

Christopher J Hoffmann1, Salome Charalambous, Katherine L Fielding, Craig Innes, Richard E Chaisson, Alison D Grant, Gavin J Churchyard.   

Abstract

In 2007, the WHO recommended a maximum stavudine dose of 30 mg. We compared virologic suppression among patients weighing more than 60 kg and receiving stavudine 30 mg (n = 110) versus 40 mg (n = 508) in community HIV clinics in South Africa, before and after guidelines changed. At 6 months, HIV RNA less than 400 copies/ml was achieved in 79% and 81% receiving 30 and 40 mg stavudine, respectively (chi2, P = 0.6). In regression modeling, including baseline HIV RNA and nonnucleoside reverse transcriptase inhibitor agent, stavudine dose remained unassociated with suppression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491652      PMCID: PMC2776829          DOI: 10.1097/QAD.0b013e32832e0585

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.

Authors:  Fatu Forna; Cheryl A Liechty; Peter Solberg; Fred Asiimwe; Willy Were; Jonathan Mermin; Prosper Behumbiize; Tony Tong; John T Brooks; Paul J Weidle
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-01       Impact factor: 3.731

Review 2.  Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.

Authors:  Andrew Hill; Kiat Ruxrungtham; Mattana Hanvanich; Christine Katlama; Eva Wolf; Vincent Soriano; Ana Milinkovic; Jose Gatell; Esteban Ribera
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

3.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

Authors:  F van Leth; P Phanuphak; K Ruxrungtham; E Baraldi; S Miller; B Gazzard; P Cahn; U G Lalloo; I P van der Westhuizen; D R Malan; M A Johnson; B R Santos; F Mulcahy; R Wood; G C Levi; G Reboredo; K Squires; I Cassetti; D Petit; F Raffi; C Katlama; R L Murphy; A Horban; J P Dam; E Hassink; R van Leeuwen; P Robinson; F W Wit; J M A Lange
Journal:  Lancet       Date:  2004-04-17       Impact factor: 79.321

4.  High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.

Authors:  Johan van Griensven; Ludwig De Naeyer; Thomas Mushi; Sowaf Ubarijoro; Diane Gashumba; Claire Gazille; Rony Zachariah
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-04-30       Impact factor: 2.184

5.  Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.

Authors:  Françoise Renaud-Théry; Boniface Dongmo Nguimfack; Marco Vitoria; Evan Lee; Peter Graaff; Badara Samb; Joseph Perriëns
Journal:  AIDS       Date:  2007-07       Impact factor: 4.177

6.  Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Authors:  Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

7.  Design and implementation of the stavudine parallel-track program.

Authors:  R E Anderson; L M Dunkle; L Smaldone; M Adler; C Wirtz; D Kriesel; A Cross; R R Martin
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

8.  Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

Authors:  H W Murray; K E Squires; W Weiss; S Sledz; H S Sacks; J Hassett; A Cross; R E Anderson; L M Dunkle
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

9.  Dose-related activity of stavudine in patients infected with human immunodeficiency virus.

Authors:  E A Petersen; C H Ramírez-Ronda; W D Hardy; R Schwartz; H S Sacks; S Follansbee; D M Peterson; A Cross; R E Anderson; L M Dunkle
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

10.  Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.

Authors: 
Journal:  AIDS       Date:  2006-06-26       Impact factor: 4.177

View more
  6 in total

1.  In silico study supports the efficacy of a reduced dose regimen for stavudine.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2011-08-22       Impact factor: 5.970

2.  Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.

Authors:  Mhairi Maskew; Daniel Westreich; Matthew P Fox; Thapelo Maotoe; Ian M Sanne
Journal:  J Int AIDS Soc       Date:  2012-03-12       Impact factor: 5.396

3.  Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.

Authors:  Erik Mossdorf; Marcel Stoeckle; Emmanuel G Mwaigomole; Evarist Chiweka; Patience L Kibatala; Eveline Geubbels; Honoraty Urassa; Salim Abdulla; Luigia Elzi; Marcel Tanner; Hansjakob Furrer; Christoph Hatz; Manuel Battegay
Journal:  BMC Infect Dis       Date:  2011-04-19       Impact factor: 3.090

4.  Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Authors:  Alana T Brennan; Mhairi Maskew; Prudence Ive; Kate Shearer; Lawrence Long; Ian Sanne; Matthew P Fox
Journal:  J Int AIDS Soc       Date:  2013-11-19       Impact factor: 5.396

Review 5.  Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis.

Authors:  Fabien Taieb; Yoann Madec; Amandine Cournil; Eric Delaporte
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

6.  Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi.

Authors:  Joep J van Oosterhout; Jane Mallewa; Symon Kaunda; Newton Chagoma; Yassin Njalale; Elizabeth Kampira; Mavuto Mukaka; Robert S Heyderman
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.